Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population
Primary Purpose
Fibromyalgia, Pain
Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
PRIMA Device
Sponsored by
About this trial
This is an interventional treatment trial for Fibromyalgia focused on measuring Chronic musculoskeletal pain secondary to Fibromyalgia
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of chronic musculoskeletal pain of at least six months duration secondary to FMS using American College of Rheumatology (ACR) criteria and with the minimum of 11 of 18 defined tender points, measured by dolorimeter at a threshold of up to 4 kg of pressure
- Males and females, 18 years and older
- Able to complete assessment index forms unaided by caregiver/interpreter
- Pain score of 4 or greater on the Numerical Rating Scale (NRS), averaged from the Baseline Period scores recorded on the 7 days immediately prior to randomization
- Demonstration of stabilized pain scores as measured on the NRS during the Baseline Period (Days -7 to -1)
- Able to tolerate prohibition of all medications for pain, depression and sleep disorders except for acetaminophen (up to 4 g/day) and cardiac aspirin (up to 325 mg/day) demonstrated for the Stabilization and Baseline Periods prior to randomization
- Able and willing to provide a written informed consent
Exclusion Criteria:
- Unwilling or unable to sign an informed consent, or to comply with the protocol
- Evidence of inflammatory rheumatic disease, secondary fibromyalgia, or other severe painful disorders that might confound assessment of FMS pain
- Currently under treatment (pharmacological or cognitive therapy) for a Major Depressive Episode (MDE) or has demonstrated suicidal ideation in the past
- History or current treatment of migraine, tension or cluster headache requiring regular medication
- History or current treatment of seizure disorder
- History or current treatment of cancer with the exception of basal cell carcinoma and cervical dysplasia
- Cognitive dysfunction or personality disorder which would preclude self-directed treatment, self assessment and / or diary completion
- Clinically significant or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise participation
- Hearing aids, metal implants (excludes dental work) above mid torso or in the cranium (e.g. plates, implants or clips). (Metal implants in parts of the body below mid-torso, such as knee or hips replacements, clips, screws or plates to stabilize fractures are acceptable)
- Pacemakers, defibrillators, implanted neurostimulators, implanted drug pumps or other electrical implanted devices
- Insufficient knowledge of English to complete the self-assessment forms
- History of or current drug or alcohol abuse
- History of abuse of a previous physician relationship or the medical system
- Receiving disability insurance, applying for disability insurance, or engaged in litigation related to FMS
- Use of an investigational drug or device in a controlled study within 30 days
- Pregnancy (U.S. sites only)
- Breastfeeding or intending to breastfeed (U.S. sites only)
Sites / Locations
Outcomes
Primary Outcome Measures
Clinically significant pain reduction, evidenced by a statistically significant difference between active and placebo groups in percentage of subjects who achieve a pain reduction of at least 30% at week 12 as compared to the Baseline.
Secondary Outcome Measures
Additional outcome measures will include mood alteration, sleep quality, improvement of physical functioning and relief medication usage by subjects in both groups.
Full Information
NCT ID
NCT00450905
First Posted
March 21, 2007
Last Updated
October 3, 2008
Sponsor
Fralex Therapeutics
Collaborators
PharmaNet, McDougall Scientific Limited
1. Study Identification
Unique Protocol Identification Number
NCT00450905
Brief Title
Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population
Official Title
Randomized Evaluation of a Low-Frequency Investigational Device Employing Neuromodulation Therapy in Patients With Fibromyalgia
Study Type
Interventional
2. Study Status
Record Verification Date
February 2008
Overall Recruitment Status
Terminated
Study Start Date
March 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2008 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Fralex Therapeutics
Collaborators
PharmaNet, McDougall Scientific Limited
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is being performed to determine the safety and efficacy of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain associated with Fibromyalgia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia, Pain
Keywords
Chronic musculoskeletal pain secondary to Fibromyalgia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
PRIMA Device
Primary Outcome Measure Information:
Title
Clinically significant pain reduction, evidenced by a statistically significant difference between active and placebo groups in percentage of subjects who achieve a pain reduction of at least 30% at week 12 as compared to the Baseline.
Secondary Outcome Measure Information:
Title
Additional outcome measures will include mood alteration, sleep quality, improvement of physical functioning and relief medication usage by subjects in both groups.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of chronic musculoskeletal pain of at least six months duration secondary to FMS using American College of Rheumatology (ACR) criteria and with the minimum of 11 of 18 defined tender points, measured by dolorimeter at a threshold of up to 4 kg of pressure
Males and females, 18 years and older
Able to complete assessment index forms unaided by caregiver/interpreter
Pain score of 4 or greater on the Numerical Rating Scale (NRS), averaged from the Baseline Period scores recorded on the 7 days immediately prior to randomization
Demonstration of stabilized pain scores as measured on the NRS during the Baseline Period (Days -7 to -1)
Able to tolerate prohibition of all medications for pain, depression and sleep disorders except for acetaminophen (up to 4 g/day) and cardiac aspirin (up to 325 mg/day) demonstrated for the Stabilization and Baseline Periods prior to randomization
Able and willing to provide a written informed consent
Exclusion Criteria:
Unwilling or unable to sign an informed consent, or to comply with the protocol
Evidence of inflammatory rheumatic disease, secondary fibromyalgia, or other severe painful disorders that might confound assessment of FMS pain
Currently under treatment (pharmacological or cognitive therapy) for a Major Depressive Episode (MDE) or has demonstrated suicidal ideation in the past
History or current treatment of migraine, tension or cluster headache requiring regular medication
History or current treatment of seizure disorder
History or current treatment of cancer with the exception of basal cell carcinoma and cervical dysplasia
Cognitive dysfunction or personality disorder which would preclude self-directed treatment, self assessment and / or diary completion
Clinically significant or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise participation
Hearing aids, metal implants (excludes dental work) above mid torso or in the cranium (e.g. plates, implants or clips). (Metal implants in parts of the body below mid-torso, such as knee or hips replacements, clips, screws or plates to stabilize fractures are acceptable)
Pacemakers, defibrillators, implanted neurostimulators, implanted drug pumps or other electrical implanted devices
Insufficient knowledge of English to complete the self-assessment forms
History of or current drug or alcohol abuse
History of abuse of a previous physician relationship or the medical system
Receiving disability insurance, applying for disability insurance, or engaged in litigation related to FMS
Use of an investigational drug or device in a controlled study within 30 days
Pregnancy (U.S. sites only)
Breastfeeding or intending to breastfeed (U.S. sites only)
Facility Information:
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
City
Garden Grove
State/Province
California
ZIP/Postal Code
92845
Country
United States
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
City
Lancaster
State/Province
California
ZIP/Postal Code
93534
Country
United States
City
Murrieta
State/Province
California
ZIP/Postal Code
92563
Country
United States
City
Palmdale
State/Province
California
ZIP/Postal Code
93550
Country
United States
City
Gainsville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33409
Country
United States
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
City
Rochester
State/Province
New York
ZIP/Postal Code
14642-8604
Country
United States
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
City
Altoona
State/Province
Pennsylvania
ZIP/Postal Code
16602
Country
United States
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
City
Spokane
State/Province
Washington
ZIP/Postal Code
99216
Country
United States
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3Z5
Country
Canada
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 1A2
Country
Canada
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M2N 6K7
Country
Canada
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M9W 4L6
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population
We'll reach out to this number within 24 hrs